Aplagon Joins The TRACER Excellence Program to Perform In-Human Imaging Study

HELSINKI, FINLAND and GRONINGEN, THE NETHERLANDS, September 8, 2022. Today, Aplagon Oy (“Aplagon”) announced that it will start its in-human imaging study to visualize the effect of its innovative APAC compound in patients with peripheral arterial occlusive disease / critical limb ischemia. The study will be executed in collaboration with TRACER B.V. (“TRACER”), a CRO […]